Letrozole as co-treatment agent in ovarian stimulation antagonist protocol in poor responders: A double-blind randomized clinical trial
| Autor: | Zohreh Lavasani, Maryam Farid Mojtahedi, Ashraf Moini, Nazila Yamini, Ladan Kashani |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
lcsh:QH471-489 QH471-489 letrozole medicine.medical_treatment Urology Placebo fertilization in vitro lcsh:Gynecology and obstetrics Intracytoplasmic sperm injection law.invention aromatase inhibitors ovarian reserve 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine lcsh:Reproduction Ovarian reserve lcsh:RG1-991 030219 obstetrics & reproductive medicine In vitro fertilisation business.industry Letrozole Reproduction Antagonist Obstetrics and Gynecology Gynecology and obstetrics primary ovarian insufficiency Reproductive Medicine 030220 oncology & carcinogenesis RG1-991 Original Article Ovulation induction ovulation induction business medicine.drug |
| Zdroj: | International Journal of Reproductive BioMedicine, Vol 17, Pp 653-660 (2019) International Journal of Reproductive Biomedicine International Journal of Reproductive BioMedicine, Vol 17, Iss 9, Pp 653-660 (2019) |
| ISSN: | 2476-3772 |
| Popis: | Background: Ovarian stimulation (OS) for poor ovarian response (POR) patients is still a major challenge in assisted reproductive techniques. Aromatase inhibitors as co-treatment in antagonist protocol are suggested to these patients, but there are controversial reports. Objective: To evaluate the effectiveness Letrozole (LZ) as adjuvant treatment in gonadotropin-releasing hormone (GnRH)-antagonist protocol in POR patients undergoing in vitro fertilization/intracytoplasmic sperm injection cycles. Materials and Methods: This double-blind randomized clinical trial was conducted in Arash women’s hospital. One hundred sixty infertile women with POR based on Bologna criteria were allocated into two groups randomly: LZ + GnRH-antagonist (LA) and placebo + GnRH-antagonist (PA) groups. In the experimental group, the patients received 5 mg LZ on the first five days of OS with 150 IU of recombinant human follicle-stimulating hormone (rFSH) and 150 IU of human menopausal gonadotropin (HMG). The cycle outcomes were compared between groups. Results: The total number of retrieved oocytes and the metaphase II oocytes in LA-treated group were significantly higher than those in the control group (p = 0.008, p = 0.002). The dosage of hMG used and the duration of OS and antagonist administration in LZ-treated group were significantly lower than those of the control group. The number of patients with no oocyte, in the control group, was higher than the LZ-treated group, and the clinical pregnancy rate in LA-treated group (25%) was higher than the control group (18%); however, the differences were not significant statistically. Conclusion: Adding 5 mg of LZ to rFSH/hMG antagonist protocol may improve the in vitro fertilization/intracytoplasmic sperm injection cycle outcome in POR patients. Key words: Letrozole, Ovarian reserve, Primary ovarian insufficiency, Ovulation induction, Fertilization in vitro, Aromatase inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|